CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Kisspeptin 112-121 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02956447
NCT02956447Phase 2Completed
CompareCT.gov

Administration of Kisspeptin in Patients With Hyperprolactinemia

Massachusetts General Hospital·interventional·Posted Nov 7, 2016·Updated Oct 1, 2024

In Brief

A Phase 2 clinical trial evaluating Kisspeptin 112-121 and GnRH for Hyperprolactinemia and Hypogonadism. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The goal of this study is to learn more about how kisspeptin, a naturally occurring hormone, affects women with high levels of prolactin (also called hyperprolactinemia). Subjects in one group will undergo blood sampling every 10 minutes over two 12-hour periods (one 12-hour period without any intervention and one 12-hour period with intravenous (IV) kisspeptin administration). Subjects in the second group will receive subcutaneous (SC) kisspeptin every 90 minutes for eight days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperprolactinemia, Hypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 7, 2016
Enrollment StartNov 17, 2017
Primary CompletionJun 28, 2023
Study CompletionJul 29, 2023
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.7 years ago

Interventions

Kisspeptin 112-121drug

0.313 ug/kg - 2 ug/kg IV or SC

GnRHdrug

0.075 ug/kg IV